Trial Profile
Pomalidomide Plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies in Dual-Refractory Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Dec 2010
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 09 Dec 2010 New trial record
- 07 Dec 2010 Results will be ppresented at the 52nd Annual Meeting of the American Society of Hematology, according to a Celgene International Sarl media release